New PharmaLex hub in Dubai supports pharmaceutical companies with international registrations in emerging markets

PharmaLex today announced that its new Dubai hub has started operations. This will enable PharmaLex to support pharmaceutical companies with their expansion into emerging markets by providing specific regulatory services for innovative, combination, or generic medicinal products as well as medical devices.

"Through our local presence in Dubai, we are able to optimise the support for our clients with the stringent regulatory requirements which represent a significant barrier to entry in Middle and Near East countries."

"Middle and Near East countries with a favourable economic environment, strong market growth potential and governmental programs to invest in healthcare systems are increasingly important for pharmaceutical companies' registration strategies. Although progress has been made in harmonizing the regulatory environment over the last years, significant differences remain." Sabine Hauk, Chief Executive Officer, explains.

"Through our local presence in Dubai, we are able to optimise the support for our clients with the stringent regulatory requirements which represent a significant barrier to entry in Middle and Near East countries." adds Tilo Netzer Chief Operating Officer. "In addition, our new hub represents an increase in resources and flexibility for developing international submission strategies and preparing dossiers according to the customer's schedule".
www.pharmalex.com